Brief: Impact Therapeutics Says CEO Purchases 100,000 Ordinary Shares At HK$14.6105 Per Share
03/09/2026 01:03
BRIEF-Impact Therapeutics Says CEO Purchases 100,000 Ordinary Shares At HK$14.6105 Per Share Sept 3 (Reuters) - IMPACT Therapeutics Inc 7630.HK:
CEO PURCHASES 100,000 ORDINARY SHARES AT HK$14.6105 PER SHARE
Further company coverage: 7630.HK
((reuters.briefs@thomsonreuters.com))
Recent news on IMPACT Therapeutics
See all newsBrief: Impact Therapeutics Says Senaparib Submitted To European Commission For Final Marketing Authorization Decision
Brief: Impact Therapeutics Says CEO Purchases 100,000 Ordinary Shares At HK$14.6105 Per Share
Brief: IMPACT Therapeutics Signs Exclusive License Deal With Pharmanovia For Senaparib In Europe, Others
Metis TechBio, IMPACT Therapeutics shine in Hong Kong debut
Brief: Impact Therapeutics Says Final Offer Price Under Global Offering Of Hk$20.10 Per H Share